Luminate, a Galway-founded healthcare technology company operating across Ireland and the United States, has raised $21 million (€19.4 million) in an expanded Series A funding round to accelerate the rollout of home-based cancer treatment across partner oncology clinics.

The round was co-led by ARTIS Ventures and Lachy Groom, with participation from Western Alliance Life Sciences and existing investors including 8VC, Y Combinator, Atlantic Bridge, Faber and SciFounders. The latest investment brings Luminate’s total funding to more than $50 million (€46.2 million) and reflects growing interest from health systems in decentralised oncology care.

Founded in 2018 by researchers from the University of Galway, Luminate operates at the intersection of life sciences, medical devices and care delivery. The company partners with oncologists and health insurers to shift selected chemotherapy infusions from hospital settings into patients’ homes, addressing pressure on clinic capacity while reducing barriers to care.

Research cited by the company indicates that patients undergoing chemotherapy spend approximately one in three days in hospital. Luminate’s Lotus programme is designed to reduce this burden while maintaining clinical oversight, with all drugs prescribed and dispensed by the patient’s own oncologist. The company currently delivers nurse-led home cancer treatments and is progressing towards regulatory approval for patient-led infusion technologies.

The new funding will support the launch of home cancer care services at 40 partner oncology clinics ahead of the mid-2026 introduction of Luminate’s auto-injector and remote monitoring devices. Clinical studies of these technologies are expected to begin in the first half of 2026.

Discover how this funding will shape the next phase of home-based oncology care.

(Photo Credits to Luminate)